Free Trial

State Street Corp Has $7.47 Million Holdings in Cellebrite DI Ltd. (NASDAQ:CLBT)

Cellebrite DI logo with Business Services background

State Street Corp lifted its holdings in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 7.3% in the third quarter, according to its most recent filing with the SEC. The firm owned 443,700 shares of the company's stock after acquiring an additional 30,052 shares during the period. State Street Corp owned approximately 0.22% of Cellebrite DI worth $7,472,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in the business. Telemark Asset Management LLC bought a new stake in Cellebrite DI in the third quarter valued at $6,736,000. Scalar Gauge Management LLC increased its position in shares of Cellebrite DI by 15.2% during the 2nd quarter. Scalar Gauge Management LLC now owns 453,554 shares of the company's stock worth $5,420,000 after purchasing an additional 60,000 shares in the last quarter. Connors Investor Services Inc. bought a new position in Cellebrite DI during the 2nd quarter valued at about $1,803,000. Principal Financial Group Inc. acquired a new position in Cellebrite DI in the third quarter valued at about $23,402,000. Finally, Concurrent Investment Advisors LLC bought a new stake in Cellebrite DI during the second quarter worth about $835,000. 45.88% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

CLBT has been the subject of a number of research analyst reports. Craig Hallum lifted their target price on shares of Cellebrite DI from $23.00 to $24.00 and gave the company a "buy" rating in a research note on Thursday, November 7th. Needham & Company LLC lifted their price objective on Cellebrite DI from $17.00 to $21.00 and gave the company a "buy" rating in a research report on Thursday, November 7th. TD Cowen increased their target price on Cellebrite DI from $20.00 to $23.00 and gave the stock a "buy" rating in a report on Monday, September 23rd. Finally, JPMorgan Chase & Co. raised their target price on Cellebrite DI from $22.00 to $24.00 and gave the company an "overweight" rating in a research note on Monday, December 16th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $20.57.

Get Our Latest Research Report on CLBT

Cellebrite DI Trading Down 1.4 %

Shares of NASDAQ:CLBT traded down $0.31 during midday trading on Friday, hitting $22.20. The company had a trading volume of 609,105 shares, compared to its average volume of 1,180,430. The stock has a market cap of $4.57 billion, a price-to-earnings ratio of -14.32, a PEG ratio of 2.71 and a beta of 1.51. The firm has a fifty day simple moving average of $19.65 and a 200 day simple moving average of $16.54. Cellebrite DI Ltd. has a 12 month low of $7.91 and a 12 month high of $22.91.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last posted its earnings results on Wednesday, November 6th. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.09 by $0.05. Cellebrite DI had a positive return on equity of 122.59% and a negative net margin of 82.28%. The firm had revenue of $106.90 million during the quarter, compared to analysts' expectations of $102.06 million. During the same period in the previous year, the firm earned $0.09 earnings per share. The company's revenue was up 27.0% on a year-over-year basis. Equities analysts forecast that Cellebrite DI Ltd. will post 0.32 EPS for the current fiscal year.

Cellebrite DI Profile

(Free Report)

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.

Further Reading

Institutional Ownership by Quarter for Cellebrite DI (NASDAQ:CLBT)

Should You Invest $1,000 in Cellebrite DI Right Now?

Before you consider Cellebrite DI, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.

While Cellebrite DI currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Crypto Boom 2025: Bitcoin’s Rise and Trump’s Impact on the Market
Goldman Sachs’ 2025 Market Outlook: Top 3 Stock Picks
7 Stocks to Benefit From Trump’s Tariffs in 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines